My memory might not be great but it didn't fail me this time. The last time I looked at AAVs was several years ago when someone mentioned the use of nanoparticle delivery of leronlimab.

Quote:

---

AAV vectors are considered attractive vectors for gene therapy because of their high safety profile. They are low in immunogenicity and do not integrate into the host genome (i.e., they remain episomal).https://biovian.com/news/viral-vector-and-gen...ummarized/

---